Q1 FY27 results: Revenue up 34% YoY, Net Profit near 5x jump, dividend date set

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionRelated Party TransactionsResults View source PDF Explain this filing

MOREPENLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+20.5%Reaction day

₹57.40

prior close

₹60.86

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%+20.1% vs market

Pharmaceuticals peers, median of 165sector-0.0%+20.6% vs sector

On the reaction day the stock moved 20.1 pts more than Nifty Microcap 250 and 20.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+8.4

10m

+11.5

15m

+12.3

30m

+13.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+20.5+0.4+20.1-0.0+20.6

Next day

+33.6+1.7+31.9+0.0+33.6

+38.6+2.1+36.5+0.2+38.4

+39.4+2.1+37.3+0.4+39.0

+39.5+2.1+37.5+0.6+38.9

+33.8+1.9+31.9+0.8+33.0

+41.6+2.4+39.2+0.4+41.3

15d

+63.4+3.0+60.4+0.5+63.0

+97.9+3.7+94.2+1.0+96.9

+136.4+1.6+134.9+2.0+134.5

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Morepen Q1 FY27 consolidated revenue up 34% YoY to Rs 57,013 lakhs. Net profit Rs 5,635 lakhs vs Rs 1,141 lakhs, near 5x jump. EPS Rs 1.03. Board set Sept 19 record date for final dividend. Extended timeline to hive off Medical Devices into subsidiary Morepen Medipath on slump sale, flagged as a material related party transaction. Reappointed Chairman Sushil Suri for 3 more years from Oct 2026. Clean limited review.

Likely market impact

Sharp beat on revenue and profit signals strong operating momentum; hive-off and chairman re-appointment need AGM approval.